Bioheart, Inc. (OTCQB: BHRT) is an emerging enterprise in the regenerative medicine industry focused on the discovery, development and commercialization of cell-based therapeutics that prevent, treat or cure cardiovascular diseases. The company’s leading product candidate is MyoCell®, a muscle stem cell therapy that is intended to improve cardiac function in patients with severe heart damage due to a heart attack. In January, Bioheart announced plans to initiate phase III clinical studies of the candidate for the treatment of chronic heart failure in the coming months. Currently, Bioheart is aiming to achieve market approval for MyoCell in 2019.

According to the American Heart Association, approximately 4.9 million Americans are currently living with congestive heart failure, demonstrating the immense market potential for Bioheart’s primary product candidate moving forward. Using muscle stem cells known as myoblasts, MyoCell therapy addresses cardiovascular damage by promoting increased muscle formation in patients’ hearts. In clinical studies, these unique cells have survived in the low-oxygen environment of chronically damaged, scarred heart tissue better than any other cell type, and they can be genetically modified to attract the stem cells of patients in order to assist with the regenerative process.

In addition to the development of cell-based therapeutics, Bioheart promotes revenue through physician and patient-based regenerative medicine training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals and the operation of a cell therapy clinic. In the first quarter of 2015, the company leveraged these products and services to realize an increase in year-over-year revenues of nearly 25 percent, recording $490,000 for the period. In the future, Bioheart’s management team expects these revenue-generating operations to provide necessary funding to support the company’s clinical development activities, as well as general business expenses.

“We continue to advance on our plan and pathway to profitability,” Mike Tomas, president and chief executive officer of Bioheart, stated in a news release. “We remain confident in our abilities and steadfast on our objectives and desire to create positive outcomes for our patients and positive investment outcomes for our shareholders.”

For prospective shareholders, Bioheart represents an intriguing investment opportunity. The company’s unique combination of promising therapeutic candidates and revenue-generating capabilities could provide it with a platform upon which to realize sustainable growth in market share and improved financial results in the years to come.

For more information, visit www.bioheartinc.com

SofTech, Inc. (OTCQB: SOFT) enhances customer productivity and promotes profitability through the development, marketing and distribution of computer software solutions for the product lifecycle management (PLM) industry. In particular, the company’s proprietary ProductCenter® PLM solution enables users to automate product data and lifecycle processes, allowing for streamlined management of product development from concept to commercialization and beyond. Currently, over 100,000 users benefit from SofTech’s innovative portfolio of software solutions and services, including employees of General Electric Company (GE), Goodrich, Honeywell (HON), AgustaWestland and the U.S. Army.

In recent months, SofTech has leveraged the marketability of its PLM solutions to record strong financial results. Despite a year-over-year decrease in total revenues following the sale of its CADRA product line, the company recorded a 20.5 percent year-over-year increase in ProductCenter revenue in the fiscal quarter ending February 28, 2015, as two of the company’s existing customers significantly escalated their usage of the product. Moving forward, SofTech will look to build on this progress by expanding its industry reach.

“The sale of the CADRA product line in 2014 provided the capital and the flexibility for us to make a significant current year investment in the development of a new PLM-based product aimed at the consumer market,” Joe Mullaney, chief executive officer of SofTech, stated in a news release. “We believe this product has the potential to get SofTech on a revenue growth path, an essential element of shareholder value enhancement.”

Through the continued expansion of its portfolio, SofTech could be in a strong position to capitalize on the growth of the PLM industry in the years to come. According to a report by Transparency Market Research, the global PLM market is expected to grow at a compound annual growth rate of 8.1 percent from 2015 to 2022, reaching a market value of more than $75.8 billion by the end of the period. Rising demand for product innovation and enhanced productivity are expected to dramatically increase the deployment of PLM solutions in non-traditional end-use sectors, including consumer products and retail.

With over 45 years of industry experience, SofTech is an established player in the expanding PLM industry. Look for the company to leverage this positioning in order to promote continued adoption of its ProductCenter solution and prepare for the commercial launch of its groundbreaking consumer market-centric product in the coming weeks.

For more information, visit www.softech.com

When oil is produced, associated gas is also produced from the reservoir together with the oil. A large amount of this gas is used due to the fact governments and oil companies have made sizeable investments to capture it. As a result, some of it is flared because of technical, regulatory, or economic constraints. Subsequently, thousands of gas flares at oil production sites worldwide burn in the range of 140 billion cubic meters of natural gas per year resulting in more than 300 million tons of CO2 getting pushed into a once pristine atmosphere.

Gas flaring is an adverse component in climate change and impacts the environment through emission of black carbon, CO2 and a myriad of other pollutants. It also wastes a valuable energy resource that could be used to advance the sustainable development of producing countries. For example, if this amount of gas were used for power generation, it could provide about 750 billion kWh of electricity, which amounts to more than the African continent’s current annual electricity consumption.

Well Power (OTCQB: WPWR) is focused on ways it can help curb gas flaring, a gnawing and growing problem in the United States. As evidence of its endeavors, the company has acquired an exclusive license to distribute ME Resources’ micro refinery unit (MRU) and has been persistent in promoting this flare-reducing technology to interested investors.

The company is active in adding talented, human capital its operations. Earlier this year, WPWR increased the seats on its board of directors to include Robert V. Shields. Mr. Shields’ impressive skill set is derived from entrepreneurship, professional engineering of more than three decades as well as tenure within the petroleum industry veteran. Specifically, Mr. Shields’ petroleum industry experience comes from the economic evaluations, drilling, production operations, and identifying and securing international exploration mineral leases.

Well Power is a development stage company that focuses on distributing micro-refinery units in Texas and internationally. The company intends to provide oil and gas producers solutions to process wasted natural gas, including stranded, shut-in, flared, and vented gas; and produce engineered fuel and electrical power.

For more information on the company, visit www.wellpowerinc.com

Let us hear your thoughts: Well Power Inc. Message Board

ContraVir Pharmaceuticals, Inc. (NASDAQ: CTRV) is a biopharmaceutical company focused on the development of targeted antiviral therapies. The company’s leading product candidate, FV-100, is currently in phase III clinical development for the treatment of shingles, as well as for the prevention of debilitating shingles-associated pain known as post-herpetic neuralgia (PHN). Additionally, ContraVir’s product pipeline includes CMX157, which is scheduled to be evaluated in a phase II clinical study for the treatment of hepatitis B virus in the coming months.

While there are already antivirals approved to treat the viral infection underlying shingles, there are currently no approved antiviral therapies for the prevention of PGN. According to a report by the National Institute of Health, an estimated one million Americans suffer from shingles each year, and more than 65 percent of those individuals suffer from PHN for 30 days or more. In some cases, PHN symptoms can persist for well over two years if left untreated. Through the eventual commercialization of FV-100, ContraVir will gain access to this critically underserved market segment within the biopharmaceutical industry. In clinical trials, FV-100 demonstrated a clinically meaningful 37 percent reduction in the incidence of PHN versus the current standard of care.

In addition to FV-100, the company continues to make clinical progress with CMX157. In June, ContraVir took a major step in the development of CMX157 by partnering with the Baruch S. Blumberg Institute, the non-profit research sister organization of the Hepatitis B Foundation, to conduct a series of experiments with the company’s drug candidate. Specifically, these tests will focus on comparing the relative anti-hepatitis B activities of CMX157 with those of tenofovir, the current standard of care, in order to determine if the candidate has unique attributes not previously appreciated of other antiviral agents.

“The Blumberg Institute’s commitment to advancing new therapies for hepatitis B make them an ideal research and development vehicle for ContraVir,” James Sapirstein, chief executive officer of ContraVir, stated in a news release. “This association will help advance our CMX157 candidate and may further de-risk the development process going forward, as we prepare to enter phase II clinical studies.”

For prospective shareholders, ContraVir’s considerable developmental progress could foreshadow an opportunity to realize sustainable returns moving forward. Following its uplisting to the NASDAQ Capital Market earlier this year, the company is in a strong strategic position to capitalize on improved visibility in the coming months. Look for ContraVir to leverage the opportunities presented by this visibility in order to optimize market growth as it continues toward the commercialization of its advanced product pipeline.

For more information, visit www.contravir.com

Neptune Technologies & Bioressources, Inc. (NASDAQ: NEPT) is a biotechnology company focused on the development and commercialization of products derived from marine biomasses for the nutraceutical and pharmaceutical industries. Leveraging a patented extraction process, the company produces nutrient-rich oils from Antarctic krill, which provide the foundation for its business dealings. Following extraction, Neptune principally sells its krill oils under the NKO® brand through a network of distributors doing business in the U.S., European and Australian nutraceutical markets.

Since bringing its first krill oil product to market in 2003, Neptune has taken significant steps toward increasing its market share in the global nutraceutical industry. The company’s proprietary extraction process allows it to produce an oil with superior levels of EPA, DHA and antioxidants, as compared to other krill oils. As a result, NKO products provide broad, clinically proven support for a collection of health issues. In 2014, Neptune expanded on these benefits by introducing three condition-specific oil blends – including NKO Beat, NKO Focus and NKO Flex – specially formulated to support heart, brain and joint health, respectively.

Last year, Neptune set the stage for continued market growth by launching operations at its new manufacturing facility in Sherbrooke, Quebec. The company’s new plant provides it with the means to address manufacturing challenges unique to krill oil production, affording Neptune an opportunity to optimize operational efficiency while promoting sustainable financial growth. The new facility currently has an annual krill oil production capacity of 150 metric tons, and the company has indicated that expansion efforts could double this capacity in the future.

“Our business has a solid foundation, built on science, intellectual property and entrepreneurship,” Jim Hamilton, president and chief executive officer of Neptune, stated in a news release. “Our key priority is to optimize our plant’s utilization, while producing the industry benchmark krill oil, NKO.”

In the first quarter of 2015, Neptune built on its recent progress by recording strong financial results. In addition to realizing a 10 percent year-over-year increase in revenue for the period, the company made significant headway toward continued improvement by streamlining production processes. For prospective shareholders, these efforts could foreshadow an opportunity to realize considerable returns in the years to come. Look for Neptune to continue expanding its effective production capacity in line with increasing commercial demand moving forward.

For more information, visit www.neptunebiotech.com

Demand for retro gaming appears to be at an all-time high. Within the past few months, promotions for a major film based on classic arcade game characters and a host of old school gaming festivals around the country have illustrated the current state of the nostalgic gaming niche. Put simply, the market potential offered by vintage video games is nearly limitless, and the rapid adoption of smartphones makes meeting this potential more accessible than ever before. WRIT Media Group, Inc. (OTCQB: WRIT), through wholly-owned subsidiary Retro Infinity, Inc., is capitalizing on this demand by bringing some of the most popular retro gaming titles of all time straight to consumers’ pockets.

“The mobile gaming industry size is projected to be over $20 billion by 2016, and retro gaming is a huge part of that,” Eric Mitchell, chief executive officer of WRIT, stated in a video interview. “Our company… has the ability to generate substantial revenue over the next 6-12 months based on our business model which is inexpensively licensing video game titles and quickly getting them into the marketplace on one of the biggest electronic platforms available right now, which is the smartphone.”

By targeting the smartphone app market, WRIT is in a strong strategic position to promote growth moving forward. According to a report by Bluecloud Solutions, mobile app usage grew by more than 75 percent in 2014, with the average U.S. consumer downloading 8.8 apps per month. Traditionally, developing gaming apps is an extremely costly venture. Estimates vary wildly depending on the type of gaming title being produced, but it’s not uncommon for mobile games to exceed $100,000 in production costs. By licensing retro gaming titles and utilizing an emulation software, WRIT is able to access the booming mobile gaming industry without the large budgetary and scheduling considerations required to produce original content.

The company’s library of classic gaming titles, which builds on the Amiga, Atari and MS-DOS brands, is available for purchase through an online point-of-sale platform. Additionally, WRIT will provide access to its licensed titles through an app for popular smartphone operating systems, including Android and iOS. Unlike most game developers, WRIT is able to minimize risk by providing proven titles to a market that is hungry for retro options. This predictability is expected to provide a competitive advantage with which the company can successfully capitalize on specific market demand while building value for shareholders.

For more information about the company, visit www.writmediagroup.com

Let us hear your thoughts: WRIT Media Group, Inc. Message Board

Los Angeles-based Giggles N’ Hugs, Inc. is a first-of-its-kind, award-winning family restaurant and play space that combines organic gourmet food with the play elements for children in a 2500-square-foot play space in the middle of the restaurant. The concept is similar to Chuck E. Cheese, but offers a unique healthier, high-end version for health conscious parents and families. Parents eat and relax while the kids have an incredible time playing in the custom-made play area with giant climbers, dragons, castles, pirate ships slides and swings and a multitude of other toys.

In addition to nightly shows and concerts, every 30 minutes Giggles N’ Hugs provides an activity such as face painting, disco dance parties, karaoke, games, arts and crafts, and much more. Giggles N’ Hugs has been voted the No. 1 family restaurant, No. 1 birthday party place, and the No. 1 indoor play space in all of Los Angeles, and has attracted a star-studded list of customers including Sandra Bullock, Heidi Klum, Jessica Alba, Halle Berry, Jennifer Garner and Ben Affleck, Denis Quaid, Mark Whalberg, Adam Sandler, Dustin Hoffman and many more.

Revenue is derived from several sources, including food and beverage sales, beer and wine, birthday parties (40%), admission and membership fees to play, along with retail sales. These revenue-generating locations are also highly sought-after tenants. The company currently has three locations in the top premier malls around Los Angeles; four of the largest mall owners in the country are giving Giggles N’ Hugs up to 75% discounts on rent and providing upward of $700,000 of upfront cash for each location to get Giggles N’ Hugs into their malls around the country.

Growth and recognition of this caliber are driven by a very powerful management team. Giggles N’ Hugs President John Kaufman was the COO at California Pizza Kitchen when the founders had just two locations. Joined by Giggles N’ Hugs’ CFO Phillip Gay, who at the time was CFO of California Kitchen, Kaufman grew the company from two to more than 100 locations – at which time it was bought by Pepsi Co. Kaufman was recruited as president of Koo Koo Roo Chicken, one of the fastest growing fast-casual concepts on the west coast, while Gay joined Wolfgang Puck Restaurants group as CFO, eventually becoming the CEO.

Giggles N’ Hugs was founded as a truly “kid friendly” establishment catered specifically to the size, interests, and nutrition needs of children. Since opening its first Giggles N’ Hugs in 2009, the company has received a steady stream of interest from more than 300 interested parties looking to expand the concept – via franchise or master licenses – in the U.S. as well globally in countries such as Germany, England, Dubai, Russia, Colombia, Australia , Singapore, Turkey, among the many more.

For more information, visit: www.gigglesnhugs.com

Let us hear your thoughts: Giggles ‘N Hugs, Inc. Message Board

Cempra is a clinical-stage pharmaceutical company focused on the development of antibacterial products to meet critical medical needs in the treatment of infectious bacterial diseases. The company’s product pipeline includes two leading candidates in advanced clinical development. Solithromycin, Cempra’s first candidate, is currently being evaluated in phase III clinical studies for the treatment of community acquired bacterial pneumonia (CABP) and uncomplicated bacterial urethritis caused by Neisseria gonorrhea and chlamydia. Taksta™, Cempra’s second candidate, is being developed for chronic oral treatment of refractory infections in bones and joints.

Additionally, with funding provided by the Biomedical Advanced Research Development Authority (BARDA), Cempra is currently conducting a phase Ib clinical trial to evaluate solithromycin as a pediatric treatment for respiratory tract infections. This program, which was initiated earlier this year, represents the first development of a pediatric suspension formulation of an antibiotic for the treatment of respiratory tract infections in more than 20 years.

In the first quarter of 2015, Cempra reported positive topline results from its initial phase III clinical trial of solithromycin for the treatment of CABP. According to the report, the product candidate performed on pace or better than the current standard of care in sustainability of clinical response at all studied durations.

“Cempra is off to a great start in 2015 and I am pleased that we have achieved enrollment of 610 patients in the… phase III clinical trial in CABP,” Dr. Prabhavathi Fernandes, president and chief executive officer of Cempra, stated in a news release. “Our initial commercial preparations for solithromycin are also underway as we continue our market research activities to assess the commercial potential for this exciting new antibiotic.”

When commercialized, solithromycin for the treatment of CABP should provide Cempra with a platform to realize sustainable market growth in the future. CABP is currently one of the most commonly diagnosed bacterial infections in the United States, with an estimated five to ten million cases recorded each year. Because many strains of the infection have become resistant to currently-approved antibacterial drugs, the market demand for solithromycin is expected to be immense in the years to come.

The continued development of Cempra’s advanced product pipeline should provide channels for the company to realize improved investor returns. For prospective shareholders, this potential makes Cempra an intriguing investment opportunity in the months ahead. Look for the company to continue making strides toward the eventual commercialization of its leading product candidates in order to bolster its financial growth moving forward.

For more information, visit www.cempra.com

ImageWare Systems, Inc. (OTCQB: IWSY) is a leading developer of mobile and cloud-based identity management solutions – including biometric, secure credential and law enforcement technologies. The company’s fully-scalable biometric product line delivers multi-modal identity management capabilities for user authentication both on premises and in the cloud. Through its GoCloudID® and GoMobile Interactive® offerings, ImageWare provides customers in a collection of markets an innovative approach to easily adding a secure layer of biometric authentication to a variety of platforms and services.

In recent months, ImageWare has targeted large IT service providers in order to maximize its market presence moving forward. Through this strategy, the company has formed significant relationships with a collection of major industry players and promising startups – including Fujitsu, TransUnion, CA Technologies, IBM, Deutsche Telekom, Agility and Extenua. While these partners remained in the testing and implementation phase of adopting ImageWare’s identity management solutions throughout the first quarter of 2015, the company’s management team is optimistic about the opportunities these relationships could present in the future.

“While we certainly expected some of these agreements to be producing revenues today, it is important to note that we are dealing with large organizations that are thoughtful and methodical about the rollout of our transformational software,” Jim Miller, chairman and chief executive officer of ImageWare, stated in a news release. “As such, we remain undeterred by the pace of the rollout and steadfast in our goal to transform ImageWare in to a commercial-based provider of biometrics-as-a-service – a transition we expect to drive significant shareholder value.”

In addition to this progress, ImageWare completed its first SaaS installation and initiated revenue generation on a per transaction basis with its GoCloudID product in the first quarter. GoCloudID differentiates itself from the competition as the only hosted biometric identity management solution on the market that allows for easy adoption with no start-up costs. The system, which was deployed for the Baja California driver’s license program, is expected to provide fingerprint and facial recognition biometrics for more than 80,000 current users as well as support the production of additional users at a rate of nearly 20,000 per month.

For prospective investors, the company’s recent actions could set the stage for sustainable returns in the months to come. Look for ImageWare to leverage its existing industry partnerships in order to promote improved financial results in the future.

For more information, visit www.iwsinc.com

Aristocrat Group Corp. identifies and promotes unique brands that have mass market appeal across diverse demographics. The company is also keen on emerging and re-emerging trends, as well as the opportunities they provide. Last month the company, building on the increasing favor for boxed wine, introduced Big Box Vodka, an ultra-premium distilled spirit made in the U.S. using Idaho Winter Wheat and pure Rocky Mountain water in a four-column distillation process.

Each box contains 1.75 liters—more than double the amount inside traditional 750 ml bottles— without taking up more space. Big Box Vodka’s groundbreaking packing is composed of microflute cardboard, which provides superior durability and insulation. Every box contains a spouted, inner beverage bladder that can be removed for faster cooling times.

While the bag-in-box packaging concept was initially associated with generic, inexpensive, or unpalatable wines, high-end bag-in-box wines are now commonplace and well-reviewed. They are also earning increasing market share in the broader wine market.

ASCC CEO Robert Federowicz said the company is creating a new market segment with its ultra-premium vodka, and that he expects to see similar strong sales growth for the bag-in-box packaging concept in the vodka market.

“Increasingly sophisticated customers have caught on to the benefits of bag-in-box packaging, such as a longer shelf life after opening, easy handling, a lower price per liter and significant environmental advantages,” Federowicz stated in the news release. “The time is now right for the bag-in-box concept to make a splash in the vodka industry, too.”

Plans call for Big Box Vodka to be debuted simultaneously this summer at retail outlets in California, Nevada, Florida, Louisiana and Texas, representing a huge population of more than 90 million people—nearly 30 percent of the total U.S. populace. ASCC’s flagship brand, RWB Ultra-Premium Handcrafted Vodka, is already available online and at many bars and retailers.

For more information visit www.aristocratgroupcorp.com/investors

Let us hear your thoughts: The Aristocrat Group Corp. Message Board